A comparative study to evaluate the Q3 characteristics of different tretinoin microspheres available in the Indian market to the innovator or the reference listed drugs

Monika Chinda; K. Balakrishna Patro; Ravish Qureshi; Amol Langde; Anil Kukreja; Hiren Patel

doi:10.18203/issn.2455-4529.IntJResDermatol20253295

Authors

Monika Chinda Department of Medical Affairs, Emcutix Biopharmaceutical Limited, Mumbai, Maharashtra, India
K. Balakrishna Patro Department of Formulation and Development, Encube Advance Research Center, Kalyan, Maharashtra, India
Ravish Qureshi Department of Formulation and Development, Encube Advance Research Center, Kalyan, Maharashtra, India
Amol Langde Department of Analytical Services – IVRT, Encube Advance Research Center, Kalyan, Maharashtra, India
Anil Kukreja Department of Clinical Research and Medical Affairs, Emcure Pharmaceutical Limited, Mumbai, Maharashtra, India
Hiren Patel Department of R&D and MSTG, Emcure Pharmaceutical Limited, Pune, Maharashtra, India

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20253295

Keywords:

Microsphere, Tretinoin, Q3 microstructure, Similarity

Abstract

Background: With the increasing availability of tretinoin microsphere gels in the Indian pharmaceutical market, comparative evaluation against market products and the U.S. reference listed drug (RLD) becomes essential to assess quality, safety, and performance consistency.

Methods: This study presents a comprehensive Q3 characterization a test product with 0.04% marketed by Emcutix in comparison with the U.S. RLD, retin-A micro gel, and various Indian marketed tretinoin gel brands A, B, and C (0.04% tretinoin). The evaluation focused on key physicochemical and structural attributes including appearance, texture, pH, drug content, viscosity, specific gravity, phase morphology, and in vitro release testing (IVRT).

Results: The test product 0.04% exhibited visual appearance, texture, pH, and tretinoin content similar to RLD. In contrast, the marketed products demonstrated deviations in appearance and suboptimal drug content, failing to meet USP and BP overage allowances. Viscosity (38,000 cPs) and specific gravity (1.047) of the test product 0.04% were within acceptable ranges, closely matching the RLD values. Microsphere morphology revealed well-formed, spheroidal particles in test product 0.04% and brand A formulation, while brand C and Brand B lacked such microsphere structures. IVRT profiles showed that the test product and brand A formulation showed the slowest, most sustained release, whereas brand B and brand C showed faster release kinetics, correlating with the absence of microspheres.

Conclusions: Overall, the test product gels demonstrate Q3 equivalence to the RLD and outperform Indian market products in structural and release characteristics, suggesting their suitability for bioequivalence and regulatory alignments.

Metrics

Metrics Loading ...

References

Kligman AM. The growing importance of topical retinoids in clinical dermatology: a retrospective and prospective analysis. J Am Acad Dermatol. 1998;39(2 Suppl):S2-7. DOI: https://doi.org/10.1016/S0190-9622(98)70437-2

Baldwin H, Webster G, Gold LS, Callender V, Cook-Bolden FE, Guenin E. 50 years of topical retinoids for acne: evolution of treatment. Am J Clin Dermatol. 2021;22(3):315-27. DOI: https://doi.org/10.1007/s40257-021-00594-8

Yoham AL, Casadesus D. Tretinoin. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2023.

Sumita JM, Leonardi GR, Bagatin E. Tretinoin peel: a critical view. An Bras Dermatol. 2017;92(3):363-6. DOI: https://doi.org/10.1590/abd1806-4841.201755325

Goldfarb MT, Ellis CN, Voorhees JJ. Topical tretinoin: its use in daily practice to reverse photoageing. Br J Dermatol. 1990;122(s35):87-91. DOI: https://doi.org/10.1111/j.1365-2133.1990.tb16131.x

Bulengo-Ransby SM, Griffiths C, Kimbrough-Green CK, Finkel LJ, Hamilton TA, Ellis CN, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in Black patients. N Engl J Med.1993;328(20):1438-43. DOI: https://doi.org/10.1056/NEJM199305203282002

Sitohang IBS, Makes WI, Sandora N, Suryanegara J. Topical tretinoin for treating photoaging: a systematic review of randomized controlled trials. Int J Womens Dermatol. 2022;8(1):e003. DOI: https://doi.org/10.1097/JW9.0000000000000003

Rahman SA, Abdelmalak NS, Badawi A, Elbayoumy T, Sabry N, Ramly AE. Formulation of tretinoin-loaded topical proniosomes for treatment of acne: in vitro characterization, skin irritation test and comparative clinical study. Drug Deliv. 2014;22(6):731-9. DOI: https://doi.org/10.3109/10717544.2014.896428

Rahman SA, Abdelmalak NS, Badawi A, Elbayoumy T, Sabry N, Ramly AE. Tretinoin-loaded liposomal formulations: from lab to comparative clinical study in acne patients. Drug Deliv. 2015;23(4):1184-93. DOI: https://doi.org/10.3109/10717544.2015.1041578

Patel VB, Misra A, Marfatia YS. Topical liposomal gel of tretinoin for the treatment of acne: research and clinical implications. Pharm Dev Technol. 2000;5(4):455-64. DOI: https://doi.org/10.1081/PDT-100102029

Samadi A, Sartipi Z, Nasrollahi SA, Sheikholeslami B, Kashani MN, Rouini MR, et al. Efficacy assessments of tretinoin-loaded nano lipid carriers in acne vulgaris: a double blind, split-face randomized clinical study. Arch Dermatol Res. 2021;314(6):553-61. DOI: https://doi.org/10.1007/s00403-021-02256-5

Del Rosso J, Sugarman J, Green L, Lain T, Levy-Hacham O, Mizrahi R, et al. Efficacy and safety of microencapsulated benzoyl peroxide and microencapsulated tretinoin for the treatment of acne vulgaris: results from two phase 3 double-blind, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2023;89(4):719-27. DOI: https://doi.org/10.1016/j.jaad.2023.05.093

Špaglová M, Papadakos M, Čuchorová M, Matušová D. Release of tretinoin solubilized in microemulsion from Carbopol and Xanthan gel: in vitro versus ex vivo permeation study. Polymers. 2023;15(2):329. DOI: https://doi.org/10.3390/polym15020329

Elfakhri KH, Niu M, Ghosh P, Ramezanli T, Raney SG, Ahmed S, et al. Physicochemical and structural evaluation of microparticles in tretinoin topical gels. Int J Pharm. 2022;620:121748. DOI: https://doi.org/10.1016/j.ijpharm.2022.121748

Elfakhri KH, Niu M, Ghosh P, Ramezanli T, Raney SG, Kamal N, et al. Understanding the impact of formulation design on microstructure and drug release from porous microparticle-based tretinoin topical gels. Int J Pharm. 2024;653:123794. DOI: https://doi.org/10.1016/j.ijpharm.2024.123794

U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs. Available at: https://www. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. Accessed on 21 August 2025.

Food and Drug Administration. Draft guidance on tretinoin. 2022. Available at: https://www.access data.fda.gov/drugsatfda_docs/psg/PSG_017579.pdf. Accessed on 21 August 2025.

Food and Drug Administration. Draft guidance on tretinoin. 2024. Available at: https://www.access data.fda.gov/drugsatfda_docs/psg/PSG_020475.pdf. Accessed on 21 August 2025.

Bausch Health US, LLC. Highlights of prescribing information. 2025. Available at: https://pi. bauschhealth.com/globalassets/BHC/PI/Retin-A-Micro-Gel-PI.pdf. Accessed on 21 August 2025.

Valeant Pharmaceuticals North America LLC. Highlights of prescribing information. 2014. Available at: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2014/020475s021lbl.pdf. Accessed on 21 August 2025.

Parab PV, Co BMS. Storage stable tretinoin and 4-hydroxyanisole containing topical composition. US patent US6353029B1. 2000. Available at: https://patents.google.com/patent/US6353029B1/en. Accessed on 21 August 2025.

Shanley A. Topical formulation: moving from art to science. PharmTech. 2025. Available at: https://www.pharmtech.com/view/topical-formulation-moving-art-science. Accessed on 21 August 2025.

Shin S, Kim H, Oh I, Cho C, Yang K. Development of tretinoin gels for enhanced transdermal delivery. Eur J Pharm Biopharm. 2005;60(1):67-71. DOI: https://doi.org/10.1016/j.ejpb.2005.01.008

Prakash C, Bhargava P, Tiwari S, Majumdar B, Bhargava RK. Skin surface pH in acne vulgaris: insights from an observational study and review of the literature. J Clin Aesthet Dermatol. 2017;10(7):33-9.

Center for Drug Evaluation and Research. Guidances. Drugs. U.S. Food and Drug Administration. 2025. Available at: https://www .fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs. Accessed on 21 August 2025.